Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -34.2%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $188M | $271M | $408M | $1.0B | $512M | $1.5B | $1.4B | $593M | $410M | $466M | — |
| Enterprise Value | $195M | $279M | $389M | $895M | $218M | $1.2B | $1.2B | $491M | $372M | $396M | — |
| P/E Ratio → | -1.59 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.35 | 1.96 | 3.01 | 8.48 | 4.86 | 13.81 | 15.93 | 10.45 | 10.88 | 20.37 | — |
| P/B Ratio | 0.58 | 0.92 | 1.24 | 2.94 | 1.43 | 3.46 | 6.68 | 4.61 | 9.86 | 7.08 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.01 | 2.87 | 7.39 | 2.06 | 10.42 | 14.18 | 8.66 | 9.88 | 17.30 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.7% | 46.7% | 59.9% | 60.3% | 43.0% | 58.6% | 55.8% | 47.3% | 47.8% | 43.7% | 44.1% |
| Operating Margin | -79.2% | -79.2% | -38.8% | -38.0% | -98.8% | -51.1% | -36.6% | -73.3% | -83.8% | -113.7% | -123.5% |
| Net Profit Margin | -77.3% | -77.3% | -28.4% | -23.4% | -94.4% | -50.2% | -36.5% | -71.9% | -82.5% | -118.1% | -131.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -34.2% | -34.2% | -11.3% | -8.0% | -24.9% | -17.2% | -18.8% | -47.9% | -57.8% | -68.1% | -172.0% |
| ROA | -26.0% | -26.0% | -9.2% | -6.6% | -21.2% | -14.3% | -14.3% | -34.3% | -39.0% | -41.9% | -104.2% |
| ROIC | -26.8% | -26.8% | -15.0% | -24.6% | -120.6% | -69.7% | -57.4% | -201.8% | -631.0% | — | — |
| ROCE | -31.0% | -31.0% | -14.0% | -11.6% | -23.9% | -16.1% | -16.6% | -41.6% | -51.7% | -52.9% | -168.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.11 | 0.12 | 0.12 | 0.05 | 0.15 | 0.06 | 0.18 | 0.14 | 0.76 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.03 | -0.06 | -0.38 | -0.82 | -0.85 | -0.73 | -0.79 | -0.91 | -1.07 | -1.44 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -140.25 | -115.69 | — | — | -27.38 | -16.85 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | 2.84 | 8.66 | 9.80 | 12.17 | 12.14 | 5.52 | 6.69 | 3.43 | 4.53 | 3.22 |
| Quick Ratio | 2.11 | 2.11 | 7.88 | 9.13 | 11.63 | 11.54 | 5.14 | 6.16 | 3.09 | 4.35 | 3.08 |
| Cash Ratio | 1.58 | 1.58 | 6.88 | 8.24 | 10.81 | 10.72 | 4.56 | 5.50 | 2.57 | 4.04 | 2.71 |
| Asset Turnover | — | 0.33 | 0.33 | 0.28 | 0.24 | 0.22 | 0.32 | 0.33 | 0.56 | 0.25 | 0.47 |
| Inventory Turnover | 1.35 | 1.35 | 1.66 | 1.84 | 3.55 | 2.06 | 2.57 | 2.86 | 3.30 | 3.61 | 6.44 |
| Days Sales Outstanding | — | 78.90 | 86.62 | 76.57 | 65.78 | 78.53 | 72.61 | 70.16 | 65.88 | 89.34 | 81.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $43M | $38M | $38M | $37M | $36M | $30M | $25M | $22M | $22M | $16M |
Imminent liquidity shortfall
According to current market data, QTRX trades at a price-to-sales multiple of 1.46, which appears to reflect significant skepticism regarding the company's ability to achieve profitability, especially when compared to the higher multiples often commanded by peers in the high-growth proteomics and diagnostic tool sectors.
The current valuation suggests that investors are heavily discounting the company's future earnings potential due to persistent net losses and a lack of clear path to positive cash flow. This multiple implies that the market is pricing the firm as a distressed asset rather than a high-growth technology provider, warranting caution regarding the sustainability of the current share price.
Based on reported financial figures, the company's ROIC has consistently remained in negative territory, reaching -10.6% in 2026Q1, which indicates that the firm is currently destroying shareholder value rather than compounding it through its investments in proteomics hardware and clinical diagnostic assay development.
The persistent negative return on invested capital suggests that the company's core business model is not yet generating sufficient returns to cover the cost of the capital deployed. Investors should monitor whether future clinical adoption can drive the necessary scale to reverse this trend, as current efficiency levels appear structurally inadequate.
As reported in recent quarterly filings, the company's cash conversion cycle has remained elevated, peaking at 250 days in 2026Q1, which highlights significant inefficiencies in managing inventory and receivables compared to the more streamlined operations typically observed in established medical device manufacturers.
The high days-in-inventory figure suggests that the company is struggling to align its production output with actual market demand, leading to capital being trapped in unsold assets. This inefficiency exacerbates the firm's liquidity constraints and suggests that operational improvements are required to optimize the cash conversion cycle.
Based on the latest financial statements, the company's cash and equivalents have dwindled to $29.8M, a figure that appears insufficient to sustain the current quarterly burn rate, indicating a highly vulnerable liquidity position that may necessitate immediate external financing to maintain ongoing operations.
The rapid depletion of cash reserves suggests that the company's current operating model is not self-sustaining, leaving little room for error in its transition to clinical markets. Investors should view this liquidity profile as a primary risk factor, as the firm's ability to fund its R&D and commercialization efforts is increasingly constrained.
Market participants frequently misapply the price-to-sales ratio to QTRX, which obscures the company's underlying cash burn and the structural limitations of its current gross margin profile, ultimately failing to account for the significant capital intensity required to scale its specialized bead-based diagnostic platform.
Using revenue multiples for a company in this stage of development ignores the critical importance of consumable pull-through and the high fixed-cost base that currently suppresses profitability. A more appropriate metric would be the cash-burn-to-liquidity ratio, which better captures the immediate survival risk inherent in the company's current financial trajectory.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QTRX stock.
Quanterix Corporation's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Quanterix Corporation's return on equity (ROE) is -34.2%. The historical average is -46.0%.
Based on historical data, Quanterix Corporation is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Quanterix Corporation has 46.7% gross margin and -79.2% operating margin.